Skip to main content
SyntekaBio,Inc. logo

SyntekaBio,Inc. — Investor Relations & Filings

Ticker · 226330 ISIN · KR7226330009 KO Professional, scientific and technical activities
Open in API
Filings indexed 322 across all filing types
Latest filing 2024-03-04 AGM Information
Country KR South Korea
Listing KO 226330

About SyntekaBio,Inc.

https://www.syntekabio.com/

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with other companies' meetings, as identified by the KOSDAQ Association. Since this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves (AGM-R) or a proxy statement (PSI), it falls under the general regulatory filing category.
2024-03-04 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Syntekabio. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2024-02-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by major shareholders and special related parties, including transaction dates, methods (market buy/sell, stock option exercise), and the purpose of holding. This fits the definition of a 'Major Shareholding Notification' (MRQ).
2024-02-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). It details the share ownership changes of a specific individual (Hong Jong-hui) who is an executive at Syntekabio. This type of filing is a standard regulatory disclosure for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2024-02-27 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Syntekabio) regarding a significant change in revenue or profit/loss structure (30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial changes. Since it provides the initial announcement of financial results and highlights key variances, it fits the definition of an Earnings Release (ER). FY 2023
2024-02-07 Korean
[기재정정]신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Syntekabio regarding a 'Correction Report' (정정신고) for a 'New Facility Investment' (신규시설투자등). It details changes to investment amounts and project status for an AI Supercomputing Center. Since this relates to capital expenditure and financing updates for company infrastructure, it falls under the 'Capital/Financing Update' category.
2024-02-05 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.